All Immuno-oncology articles – Page 2
-
ArticleHow to select the optimal bispecific antibody format for therapeutic success
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
-
ArticleDesigning antibodies to think before they bind
Standard antibody therapies bind their target and trigger a response. But what if the real breakthrough is designing antibodies that first recognise context before they act? This article looks at how bispecifics are becoming smarter, more selective and more precise.
-
ArticleOutsmarting immune suppression through GPCR innovation
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
-
ArticleHow dual-targeting ADCs aim to tackle resistance
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
-
NewsBCG alters bone marrow to strengthen anti-cancer response
A new study reveals that BCG, a decades-old bladder cancer treatment, reprograms the immune system at the bone marrow level, offering a new perspective into how this immunotherapy boosts the body’s defence against cancer.
-
ArticlePOLB 001: tackling cytokine storms before they start
Cytokine release syndrome (CRS) is a major barrier in cancer immunotherapy - but what if we could prevent it before it begins? Dr Liam Tremble, Principal Scientist at Poolbeg Pharma, discusses how POLB 001, an oral anti-inflammatory candidate, could offer a new way forward.
-
News
New data: Visugromab targets ADC resistance mechanism
CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune responses in solid tumours.
-
ArticleOptimising analytical strategies for ADC development
Antibody-drug conjugates (ADCs) are transforming cancer therapy by enabling targeted drug delivery with minimised side effects, but their complex structure presents unique challenges in bioanalysis. This article explores cutting-edge strategies for optimising ADC evaluation, from quantifying drug-to-antibody ratios (DAR) to overcoming hurdles like payload interference and stability.
-
NewsScientists develop immunotherapy to disarm fat-fuelled tumours
A new study reveals how tumours hijack fat metabolism to suppress immune responses - and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant cancers.
-
ArticleAI in drug discovery: faster, smarter, better
Claudia Zylberberg, Chair of Kosten Digital, reveals how AI is revolutionising cell and gene therapy, making drug discovery faster and more cost-effective.
-
ArticleNext-gen ADCs: Tubulis sets new standard in cancer treatment
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
-
NewsNew melanoma therapy prevents brain metastasis in preclinical studies
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
-
WebinarReprogramming immunity: designing smarter checkpoint receptor agonists
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
-
ArticleRefining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
-
NewsAI-designed CDK12/13 inhibitors target resistant cancers
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
-
NewsLeukaemia cells hit hard by innovative dual-drug approach
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
-
ArticleNew therapy shows promise in strengthening CAR-T responses
CAR-T therapy has shown effectiveness in cancer treatment, but relapse often occurs due to limited cell persistence. New strategies aim to improve CAR T-cell durability for longer lasting remission.
-
NewsNew enzyme discovery could boost cancer immunotherapy
A new discovery from the University of Geneva highlights the crucial role of the CH25H enzyme, which is found in cancerous lymphatic cells. This enzyme plays a key part in activating immune cells, opening up a promising pathway for improving the success of cancer immunotherapies.
-
NewsCoherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
-
ArticleCilta-cel: A new era in multiple myeloma treatment
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page